目的：了解真实世界过敏性紫癜患者的临床特征及中西医药物治疗临床实效,为临床诊断规范及合理用药提供参考。方法：选取全国19家三级甲等综合医院＂第一诊断＂为过敏性紫癜患者的医院信息管理系统（hospital information system,HIS）...目的：了解真实世界过敏性紫癜患者的临床特征及中西医药物治疗临床实效,为临床诊断规范及合理用药提供参考。方法：选取全国19家三级甲等综合医院＂第一诊断＂为过敏性紫癜患者的医院信息管理系统（hospital information system,HIS）数据,使用频数分析及关联规则进行数据分析。结果：在HIS数据的2110例过敏性紫癜患者中,发病年龄多为4-12岁的儿童,男性为主;住院科室多集中在儿科、皮肤科、泌尿科;近1/3人群肾脏损害和感染,西药以抗感染药物和糖皮质激素为主,代表用药为注射用氢化可的松和注射用头孢菌素类,少数患者使用免疫抑制剂如环磷酰胺;中医药治疗以清热解毒药、活血化瘀类药物为主,代表用药为丹参注射液和雷公藤多甙;大多数患者临床转归良好。结论：过敏性紫癜的患者以儿童为主。合并症主要为肾脏损害、感染,考虑感染为主要的诱发因素;临床治疗应及时控制感染,并佐以清热解毒、活血化瘀类中药辅助治疗,若出现肾脏损害早期应及时进行治疗。展开更多
目的分析真实世界人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染患者临床特征及用药规律。方法基于医院信息系统(hospital information system,HIS)真实世界数据,提取2006年1月—2011年12月全国17家三甲医院HIV感染者病历资...目的分析真实世界人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染患者临床特征及用药规律。方法基于医院信息系统(hospital information system,HIS)真实世界数据,提取2006年1月—2011年12月全国17家三甲医院HIV感染者病历资料,包括患者一般信息、疾病特征及入院期间中西药临床应用情况。结果共收集451例HIV感染者资料,有年龄记录者261例,平均36岁,其中以18~65岁居多[90.4%(236/261)];男女比例为2.8∶1;HIV患者最常入住的科室为传染病科[66.96%(302/451)],其次为呼吸科[8.2%(37/451)]。患者入院方式以门诊为主[79.6%(359/451)],其中以急诊方式入院占20.18%(91/451)。患者多因感染性疾病住院,其中以结核病最多(8.29%),其次为细菌性肺炎(6.44%)。349例有完整用药记录,共使用西药399种,中成药80种。抗微生物药使用频率最高(11.86%),以复方磺胺甲噁唑最多(2.81%)。80种中成药以清热解毒剂最常用(19.27%),其次为解表剂(10.30%)、补益剂(8.97%)、祛痰剂(7.31%)。抗微生物药联合清热解毒剂是最常见的中西药组合。451例HIV感染者经中西药治疗,病情稳定,好转率达51.2%。结论 HIV感染患者中使用频率最高西药是抗微生物类药,使用频率最高中成药为清热类药物。抗微生物药与清热解毒类中成药联合应用在临床上也较为常见。展开更多
Objective： This study aimed to prove acupuncture therapy exerted an obvious clinical efficacy in the treatment of peripheral facial neuritis in acute phase. Methods： 60 clinically collected cases were chosen in the ...Objective： This study aimed to prove acupuncture therapy exerted an obvious clinical efficacy in the treatment of peripheral facial neuritis in acute phase. Methods： 60 clinically collected cases were chosen in the study and randomly divided into control group and treatment group. In control group, dexamethasone, vitamin B, vitamin B 12, and mecobalamine were applied in acute phase, and then acupuncture therapy was combined in remission. In treatment group, western medicine combining with acupuncture therapy was used in acute phase, and three courses of treatment were totally applied. Results： The final conditions of two groups were good, and the grouping was balanced, so the comparability between them was good （P〉0.05）; the curative effects of two groups were significantly different： the effect of treatment group was better than that of control group （P〈0.01）. Conclusion： The acute phase was necessarily grasped to apply acupuncture therapy to the treatment of peripheral facial neuritis, and the curative effect would be more significant if acupuncture therapy was more early used.展开更多
OBJECTIVE: To evaluate the effect of Huadananshen mistura in clinical treatment of Chinese patients with insomnia. METHODS: In this randomized, double-blind, placebo-controlled, multi-center study, 244 patients with i...OBJECTIVE: To evaluate the effect of Huadananshen mistura in clinical treatment of Chinese patients with insomnia. METHODS: In this randomized, double-blind, placebo-controlled, multi-center study, 244 patients with insomnia were randomly assigned to a placebo group, a low-dose (10 mL/day), or a high-dose (20 mL/day) mistura group. Efficacy was assessed by using the sleep dysfunction rating scale (SDRS) and Clinical Global Impression-Improvement (CGI-I) scores. Safety and tolerability assessments included emergent adverse events, laboratory tests, and electrocardiograms. RESULTS: Total SDRS scores decreased in all three groups, and there were significant differences between the placebo group and the lowand high-dose mistura groups (P=0.000). CGI-I ratings in the lowand high-dose mistura groups were sig-nificantly better than that of the placebo group (P= 0.000). Incidences of rebound insomnia were similar in all three groups (placebo group: 6.94% , low-dose mistura group: 12.99% , and high-dose mistura group: 10.96% ; P=0.475). The efficacy of Huadananshen mistura in the lowor high-dose group was significantly better than that of the placebo group (P=0.000), but with no significant difference found between the lowand high-dose mistura groups (P=0.887). The rates of adverse events were similar in the three groups (placebo 2.44% , low-dose mistura 0%, and high-dose mistura 5%; P=0.088). CONCLUSION: Huadananshen mistura is an effective and generally well-tolerated hypnotic medicine for the treatment of Chinese patients with insomnia.展开更多
文摘目的：了解真实世界过敏性紫癜患者的临床特征及中西医药物治疗临床实效,为临床诊断规范及合理用药提供参考。方法：选取全国19家三级甲等综合医院＂第一诊断＂为过敏性紫癜患者的医院信息管理系统（hospital information system,HIS）数据,使用频数分析及关联规则进行数据分析。结果：在HIS数据的2110例过敏性紫癜患者中,发病年龄多为4-12岁的儿童,男性为主;住院科室多集中在儿科、皮肤科、泌尿科;近1/3人群肾脏损害和感染,西药以抗感染药物和糖皮质激素为主,代表用药为注射用氢化可的松和注射用头孢菌素类,少数患者使用免疫抑制剂如环磷酰胺;中医药治疗以清热解毒药、活血化瘀类药物为主,代表用药为丹参注射液和雷公藤多甙;大多数患者临床转归良好。结论：过敏性紫癜的患者以儿童为主。合并症主要为肾脏损害、感染,考虑感染为主要的诱发因素;临床治疗应及时控制感染,并佐以清热解毒、活血化瘀类中药辅助治疗,若出现肾脏损害早期应及时进行治疗。
文摘Objective： This study aimed to prove acupuncture therapy exerted an obvious clinical efficacy in the treatment of peripheral facial neuritis in acute phase. Methods： 60 clinically collected cases were chosen in the study and randomly divided into control group and treatment group. In control group, dexamethasone, vitamin B, vitamin B 12, and mecobalamine were applied in acute phase, and then acupuncture therapy was combined in remission. In treatment group, western medicine combining with acupuncture therapy was used in acute phase, and three courses of treatment were totally applied. Results： The final conditions of two groups were good, and the grouping was balanced, so the comparability between them was good （P〉0.05）; the curative effects of two groups were significantly different： the effect of treatment group was better than that of control group （P〈0.01）. Conclusion： The acute phase was necessarily grasped to apply acupuncture therapy to the treatment of peripheral facial neuritis, and the curative effect would be more significant if acupuncture therapy was more early used.
基金Supported by the Grants from National Major Project for IND(2012ZX09303-003)Shanghai Health Talent Professional Project(XBR2011049)
文摘OBJECTIVE: To evaluate the effect of Huadananshen mistura in clinical treatment of Chinese patients with insomnia. METHODS: In this randomized, double-blind, placebo-controlled, multi-center study, 244 patients with insomnia were randomly assigned to a placebo group, a low-dose (10 mL/day), or a high-dose (20 mL/day) mistura group. Efficacy was assessed by using the sleep dysfunction rating scale (SDRS) and Clinical Global Impression-Improvement (CGI-I) scores. Safety and tolerability assessments included emergent adverse events, laboratory tests, and electrocardiograms. RESULTS: Total SDRS scores decreased in all three groups, and there were significant differences between the placebo group and the lowand high-dose mistura groups (P=0.000). CGI-I ratings in the lowand high-dose mistura groups were sig-nificantly better than that of the placebo group (P= 0.000). Incidences of rebound insomnia were similar in all three groups (placebo group: 6.94% , low-dose mistura group: 12.99% , and high-dose mistura group: 10.96% ; P=0.475). The efficacy of Huadananshen mistura in the lowor high-dose group was significantly better than that of the placebo group (P=0.000), but with no significant difference found between the lowand high-dose mistura groups (P=0.887). The rates of adverse events were similar in the three groups (placebo 2.44% , low-dose mistura 0%, and high-dose mistura 5%; P=0.088). CONCLUSION: Huadananshen mistura is an effective and generally well-tolerated hypnotic medicine for the treatment of Chinese patients with insomnia.
